Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11526 posts found.

Bayer

FDA fast tracks Bayer prostate cancer drug

August 23, 2011 Sales and Marketing Algeta, Alpharadin, Bayer, prostate cancer

Bayer’s potential blockbuster prostate cancer drug Alpharadin has been granted a fast track review by the FDA, meaning it could …
News

NICE blames Faslodex rejection on uncertainties in AZ data

August 23, 2011 Sales and Marketing AstraZeneca, Faslodex, NICE, breast cancer

NICE has not recommended a high-dose form of AstraZeneca’s breast cancer drug Faslodex because of uncertainties over its cost-effectiveness. In …
News
Yervoy (ipilimumab)

BMS launches skin cancer treatment Yervoy in UK

August 22, 2011 Sales and Marketing Yervoy, cancer vaccine, ipilimumab, skin cancer

Bristol-Myers Squibb’s skin cancer treatment Yervoy has been launched in the UK for patients with the deadliest form of the …
News
double_helix_fiona_bailey

Double Helix expands strategic market research team

August 22, 2011 Medical Communications, Sales and Marketing appointment, medical communications, sales and marketing

Global market research consultancy Double Helix has appointed Fiona Bailey and  Anwar Kumi to the positions of associate director and …
Appointment
Pfizer

EMA to review two new Pfizer cancer drugs

August 19, 2011 Sales and Marketing Cancer, Pfizer, bosutinib, crizotinib

The EMA has accepted Pfizer’s regulatory submissions for two of its new cancer compounds. The first is its much-lauded crizotinib, …
News

Idea Pharma boosts project management team

August 19, 2011 Sales and Marketing appointment, sales and marketing

Phase II strategy consultancy Idea Pharma has appointed two new project managers to its team – Suzanne Axford-Bryars and Lidia …
Appointment
Roche

Roche’s Zelboraf approved by FDA months ahead of schedule

August 18, 2011 Sales and Marketing Yervoy, Zelboraf, skin cancer

The FDA has approved Roche and Daiichi Sankyo’s new skin cancer drug Zelboraf two months ahead of schedule. Zelboraf (vemurafenib) …
News
Novartis

New discount persuades NICE to back Novartis’ Tasigna

August 18, 2011 Sales and Marketing Glivec, NICE, Sprycel, Tasigna

NICE has recommended Novartis’ Tasigna for use in the NHS after the blood cancer drug’s manufacturer submitted a new patient …
News

Joint API inspection pilot proves successful

August 17, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates

Over recent years compliance with GMP in the manufacture of active substances (APIs) has been the subject of increasing regulatory …
News
Press release

NICE to review Lucentis decision

August 17, 2011 Sales and Marketing Lucentis, NICE, diabetic macular edema

NICE will allow an appeal against its decision not to recommend Novartis’s Lucentis for diabetic macular oedema. The appeal came …
News

Sanofi Pasteur MSD appoints new UK medical director

August 17, 2011 Research and Development, Sales and Marketing appointment, research and development, sales and marketing

Sanofi Pasteur MSD has appointed Dr Aidrian Kilcoyne as medical director in the UK. He joins the company from Roche …
Appointment

NICE wants more information on Pradaxa

August 17, 2011 Sales and Marketing NICE, Pradaxa

NICE has asked for more information on Pradaxa, after deciding in preliminary guidance that the drug is not cost-effective in …
News

Pfizer triumphs in US Viagra patent trial

August 17, 2011 Sales and Marketing Pfizer, generics, viagra

Pfizer has won a US patent infringement case against generics giant Teva, stopping the company from making its own version …
News

New head of oncology for Astellas Pharma Europe

August 16, 2011 Research and Development, Sales and Marketing appointment, research and development, sales and marketing

Astellas Pharma has appointed Dr Christopher Thomson as executive director of its new European Oncology Unit.   Dr Thomson will …
Appointment

Afrezza could breathe new life into inhaled insulin market

August 15, 2011 Research and Development, Sales and Marketing diabetes, inhaled insulin, insulin, research and development news

New trials for MannKind’s investigational inhaled insulin drug Afrezza have been given the go-ahead by the FDA, potentially breathing new …
News
The Gateway to Local Adoption Series

Latest content

Campaign highlights low expectations among patients with depression

May 7, 2026

Practical AI toolkit launched to help manufacturers cut through complexity

May 6, 2026

Syngene appoints Maninder Kapoor Puri as CHRO

May 6, 2026

BioPhorum acquires PharmaX Solutions

May 5, 2026

Syngene appoints Abhijit Zutshi as CCO

May 5, 2026